2013 Archived Content

SC1 Identification, Characterization and Targeting of Cancer Stem Cells 

1:00 Introduction/Welcome

1:05 New Tools and New Targets for the Development of Biotherapeutics for Cancer Stem Cells

Robert Hollingsworth, Ph.D., Director, Cancer Biology, MedImmune, Inc.

Dr. Hollingsworth will describe several new techniques for identifying, tracking, and isolating cancer stem cells (CSCs) developed at MedImmune.   These and other techniques are also being used to study possible CSC targets for drug development.

1:35 Treatment Strategies for Cancer Stem Cells from Human Prostate Cancer

Norman J. Maitland, Ph.D., Chief Scientific Officer, Procure Therapeutics Ltd


2:05 Use of Cancer Stem-Like Cell Lines from Colon, Ovary and Lung Tumors in Drug Discovery and Development

Jennie P. Mather, Ph.D., Senior Vice President, Stem Cells, Macrogenics, Inc.

The CSC hypothesis carries significant implications for cancer treatment. We selected solid tumor cancer stem-like cells (CSLC) in vitro. CSLC self-renew and form differentiated tumors. These CSLC lines provide an opportunity for developing strategies and therapeutics aimed at eliminating CSC.

2:35 Refreshment Break

2:45 Development of New Therapeutic Agents that Reduce Tumor Initiating Cell Frequency

Timothy Hoey, Ph.D., Senior Vice President, Cancer Biology, OncoMed Pharmaceuticals, Inc.

Cancer stem cells (or tumor initiating cells) mediate tumor progression, metastasis, and recurrence after therapy. We have developed new agents that block key CSC pathways including Notch and Wnt. Currently, we have three therapeutic antibodies which are in clinical testing, anti-DLL4, anti-Notch2/3, and anti-FZD, and others in pre-clinical development. These treatments inhibit tumor growth through multiple mechanisms and reduce CSC frequency.

3:15 EGFRvIII Defines a Cancer Stem Cell Hierarchy in Glioblastoma Leading to Effective Targeting with a Bispecific Antibody

Albert Wong, M.D., Professor, Cancer Biology and Neurosurgery, Stanford University Medical Center

We have found that in glioblastoma tumors, EGFRvIII, a tumor specific variant of the EGF receptor, defines a cancer stem cell hierarchy. Using anti-CD133 and anti-EGFRvIII in a bispecific antibody format to co-target these cells is an extremely effective therapeutic in vitro.

3:45 Q&A with Speakers

4:00 Close of Course


<<Back to Short Courses

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag  

Premier Sponsors

Beckman Coulter Life Sciences 

Boston Healthcare



Charles River no tagline


Cofactor Genonics


Menarini Silicon Biosystems






View All Sponsors